Novo Nordisk (NYSE:NVO) and Novartis (NYSE:NVS) have had a great start to their 2014, with shares climbing around 25% and 16%, respectively. And both pay a dividend -- Novo's is around 1.8%, while Novartis' is 3%, according to S&P Capital IQ. So they've had a great year so far, and income investors should keep an eye on them. But can they continue to outperform? Both stocks have opportunities to expand and threats from competitors coming online with new drugs.
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take on the two stocks and what they see as the opportunities and threats for each.
David Williamson owns shares of Novartis. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.